Ignite Creation Date:
2024-05-19 @ 5:33 PM
Last Modification Date:
2024-10-26 @ 3:29 PM
Study NCT ID:
NCT06410651
Status:
RECRUITING
Last Update Posted:
2024-05-13
First Post:
2024-05-05
Brief Title:
Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinoma
Sponsor:
Cancer Institute and Hospital Chinese Academy of Medical Sciences
Organization:
Cancer Institute and Hospital Chinese Academy of Medical Sciences
Study Overview
Official Title:
Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma After Failure of ChemotherapyA Phase II Study
Status:
RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Patients diagnosed with locally advanced esophageal squamous cell carcinoma ESCC who failed to induction chemoimmunotherapy had poor prognosis Radiotherpy was an important and effective treatment in treating ESCC The present study is a one-arm trial that seeks to evaluate the efficacy in patients with unresectable ESCC The study objectives include R0 resection rate complete pathological response and treatment toxicity etc
Nimotuzumab is a recombinant humanized monoclonal antibody against EGFR Its efficacy and safety in patients with esophageal cancer have been confirmed by many studies
The current prospective phase II study aimed to evaluate the efficacy and safety of a combination regimen comprising chemotherapy with nimotuzumab and S-1 and concurrent radiotherapy for patients who are not sensitive to induction chemoimmunotherapy
Nimotuzumab is a recombinant humanized monoclonal antibody against EGFR Its efficacy and safety in patients with esophageal cancer have been confirmed by many studies
The current prospective phase II study aimed to evaluate the efficacy and safety of a combination regimen comprising chemotherapy with nimotuzumab and S-1 and concurrent radiotherapy for patients who are not sensitive to induction chemoimmunotherapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None